Search Within

Paul Hamlin

Formats
  1. Meeting Abstract (183)
  2. Journal Article (101)
  3. Research Letter (7)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Population Sciences Research Program (152)
  6. Survivorship Research (145)

More Groups

People
  1. Andrew Zelenetz (186)
  2. Ariela Noy (144)
  3. Steven Horwitz (139)
  4. Maria Palomba (125)
  5. David Straus (122)
  6. Alison Moskowitz (119)

More People

Years
  1. 2025 (6)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (12)
  5. 2021 (17)
  6. 2020 (13)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (38)
  3. Hematological Oncology (15)
  4. Annals of Oncology (12)
  5. British Journal of Haematology (12)
  6. Haematologica (10)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (40)
  3. Wiley Blackwell (19)
  4. Elsevier Inc. (16)
  5. Oxford University Press (13)
  6. John Wiley & Sons (12)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Hamlin, P. A.; Musteata, V.; Zodelava, M.; Park, S. I.; Burnett, C.; Dabovic, K.; Williams, E. T.; Higgins, J. P.; Persky, D. O.
    Blood (2019)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 2 study of the dual SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Hess, B. T.; Khodadoust, M. S.; Kim, Y. H.; Munoz, J.; Patel, M. R.; Phillips, T. J.; Smith, S. D.; Smith, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Genomic profiling of mantle cell lymphoma suggests poor-risk profile is present at diagnosis and does not arise by tumor evolution
    Meeting Abstract

    Joffe, E.; Kumar, A.; Zheng, S.; Uppal, M.; Bantilan, K. S.; Atteberry, P.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of MT‐3724 to evaluate safety, pharmacodynamics and efficacy of MT‐3724 for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma
    Meeting Abstract

    Burnett, C. A.; Hamlin, P.; Dabovic, K.; Higgins, J.; Persky, D. O.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Rapid and durable responses with the SYK/JAK inhibitor cerdulatinib in a phase 2 study in relapsed/refractory follicular lymphoma - alone or in combination with rituximab
    Meeting Abstract

    Smith, S. D.; Munoz, J.; Stevens, D. A.; Smith, S. M.; Feldman, T. A.; Ye, J. C.; de Vos, S.; Hess, B. T.; Miller, C. B.; Khatcheressian, J. L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save